Romidepsin for the treatment of cutaneous T-cell lymphoma.

Drugs of today (Barcelona, Spain: 1998), 2009 - europepmc.org
Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved
in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents …
被引用次数：173 相关文章

Romidepsin for the treatment of cutaneous T-cell lymphoma

C Campas-Moya - Drugs of today (Barcelona, Spain …, 2009 - pubmed.ncbi.nlm.nih.gov
Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved
in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents …

[引用][C] Romidepsin for the treatment of cutaneous T-cell lymphoma

C Campàs-Moya - Medicamentos de actualidad= Drugs of today, 2009 - dialnet.unirioja.es

[引用][C] Romidepsin for the treatment of cutaneous T-cell lymphoma

C CAMPAS-MOYA - Drugs Today, 2009 - cir.nii.ac.jp

ROMIDEPSIN FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

C Campàs-Moya - Drugs of Today, 2009 - access.portico.org
Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved
in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents …

ROMIDEPSIN FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

C Campàs-Moya - Drugs of Today, 2009 - access.portico.org
Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved
in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents …